AbbVie Inc. [ABBV] gain 2.67% so far this year. What now?

AbbVie Inc. [NYSE: ABBV] loss -0.94% on the last trading session, reaching $139.02 price per share at the time. The company report on August 17, 2022 that Experience the JUVÉDERM® Difference with Allergan Aesthetics.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Allē Double Point Promotion Encourages Consumers to See the JUVÉDERM® Difference.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), invites consumers to experience the JUVÉDERM® difference. The JUVÉDERM® Collection of Fillers is the number one selling collection of dermal fillers on the market and offers the largest portfolio of fillers specifically designed for different areas of the face to address key patient concerns, enabling a customized treatment approach.1 Injectable dermal fillers are highly sought-after treatments among consumers who are looking to address key signs of aging or to simply accentuate what is already naturally theirs.

AbbVie Inc. represents 1.77 billion in outstanding shares, while the company has a total market value of $244.83 billion with the latest information. ABBV stock price has been found in the range of $138.45 to $140.85.

If compared to the average trading volume of 5.93M shares, ABBV reached a trading volume of 3662991 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about AbbVie Inc. [ABBV]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $159.24 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Atlantic Equities have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 01, 2022. While these analysts kept the previous recommendation, SVB Leerink raised their target price to Underperform. The new note on the price target was released on May 23, 2022, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another raise to $150, while Daiwa Securities analysts kept a Neutral rating on ABBV stock.

The Average True Range (ATR) for AbbVie Inc. is set at 2.87, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 4.27. The Price to Book ratio for the last quarter was 16.79, with the Price to Cash per share for the same quarter was set at 5.66. Price to Free Cash Flow for ABBV in the course of the last twelve months was 19.51 with Quick ratio for the last quarter at 0.70.

Trading performance analysis for ABBV stock

AbbVie Inc. [ABBV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.48. With this latest performance, ABBV shares dropped by -7.46% in over the last four-week period, additionally sinking by -4.49% over the last 6 months – not to mention a rise of 16.47% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 35.32, with the RSI for the last a single of trading hit 31.48, and the three-weeks RSI is set at 38.14 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 146.16, while it was recorded at 140.79 for the last single week of trading, and 143.44 for the last 200 days.

AbbVie Inc. [ABBV]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +35.14 and a Gross Margin at +69.49. AbbVie Inc.’s Net Margin is presently recorded at +20.41.

Return on Equity for this stock inclined to 80.52, with Return on Assets sitting at 7.72.

AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.80.

AbbVie Inc. [ABBV]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to -0.57%.

An analysis of insider ownership at AbbVie Inc. [ABBV]

There are presently around $170,336 million, or 72.30% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 153,579,751, which is approximately 2.034% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 134,700,648 shares of the stock with an approximate value of $18.73 billion in ABBV stocks shares; and STATE STREET CORP, currently with $10.72 billion in ABBV stock with ownership of nearly -1.177% of the company’s market capitalization.

Positions in AbbVie Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,291 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 73,418,100 shares. Additionally, 1,479 investors decreased positions by around 52,866,528 shares, while 398 investors held positions by with 1,098,974,517 shares. The mentioned changes placed institutional holdings at 1,225,259,145 shares, according to the latest SEC report filing. ABBV stock had 132 new institutional investments in for a total of 3,479,588 shares, while 140 institutional investors sold positions of 5,556,720 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here